brought together delegates from across the EEMEA region under the patronage of the Lithuanian Society of Laboratory Medicine. The meeting once again served as a platform to share advances and foster collaboration in autoimmunity, with a strong focus on diagnostic standardization, novel biomarkers and the integration of multi-analyte technologies into clinical practice.
The event opened with a joint session on Antiphospholipid Syndrome (APS), designed to bridge hemostasis and autoimmunity. A powerful patient testimony on surviving thrombotic events set the tone, followed by an update on evolving APS classification criteria, the use of likelihood ratios in APS diagnosis, the integration of novel biomarkers and practical strategies when the antiphospholipid (aPL) profile becomes negative.
The afternoon addressed inflammatory rheumatic diseases in Lithuania and the evolution of national diagnostic and therapeutic strategies. This led into a session on antinuclear antibodies (ANA) as an entry criterion for Systemic Lupus Erythematosus (SLE) and data comparing Particle-Based Multi-Analyte Technology (PMAT) with indirect immunofluorescence (IFA) for ANA screening. The seminar also presented the latest updates from the International Consensus on ANA Patterns (ICAP) 2025, emphasizing new HEp-2 IFA pattern classifications and their impact on standardized reporting. Additional talks explored potential triggers of autoimmunity such as Helicobacter pylori and provided local insights into inflammatory bowel disease (IBD) in Lithuania.
The second day focused on how modern technologies are reshaping autoimmunity diagnostics. Speakers reviewed the evolution of multi-analyte testing, the role of myositis-specific autoantibodies in disease classification, and how extended antibody profiling with PMAT may help predict progression from undifferentiated connective tissue disease (UCTD) to clinically overt disease. Further sessions examined Italian guidelines for the immunological diagnosis of autoimmune liver diseases in the context of EASL recommendations, emerging data on circulating calprotectin (cCLP) and the role of biomarkers in Rheumatoid Arthritis (RA) for precision medicine, including a proposed revision of RA classification criteria with an updated RF/ACPA score.
The final part of the program expanded to small-vessel vasculitis and gastrointestinal and hepatobiliary autoimmunity, highlighting the clinical relevance of ANCA and antigen-specific immunoassays, advances in celiac disease diagnostics, the significance of anti-proteinase 3 antibodies in IBD, and an overview of Primary Biliary Cholangitis (PBC) as a “disease of 100 autoantibodies.” The seminar’s rich scientific content and strong international participation confirmed its role as a key forum for advancing research, standardization and collaboration in autoimmunity across the EEMEA region. We thank all speakers and participants and look forward to welcoming you to the 13th International Autoimmunity Seminar.

Autoimmunity Booth: Virtual Reality Experience
A particularly innovative highlight was the virtual reality headset at the Autoimmunity booth. Participants could explore an immersive virtual Autoimmunity laboratory showcasing our full instrument portfolio—Aptiva, BIO-FLASH, QUANTA-Lyser 3000, NOVA View and QUANTA Link. Interactive demos with customers allowed them to experience functionalities and benefits in a realistic environment, and the initiative was met with great enthusiasm, confirming virtual reality as an effective communication and educational tool.




